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Background: Adrenocortical carcinoma (ACC) is aggressive, but rare tumours that have not been sufficiently
studied. The aim of our study was to present the demographic and clinical characteristics of patients with ACC,
to determine the overall survival rates, analyse the effect of prognostic factors on survival, as well as to identify
favorable and unfavourable predictors of survival.
Method: The study included 72 patients (42 women and 30 men) with ACC. We analysed the prognostic value
of the demographic and clinical characteristics of the patients, tumour characteristics, therapy administered and
survival rates. Kaplan-Meier survival curves and the log-rank test were used to estimate the overall and specific
survival probabilities and the Cox regression model was used to identify independent prognostic factors for survival.
Results: The patients had mean age of 50 years. The 1-, 5-, and 10-year probabilities of survival in patients with
ACC were 52.5 %, 41.1 %, and 16.4 %, respectively. The median survival time was 36 months. The results of multivariate
Cox regression analysis showed that the presence of lymphatic metastases (HR = 7.37, 95 % CI = 2.31-23.48, p = 0.001)
and therapy with mitotane (HR = 0.11, 95 % CI = 0.04-0.27, p = 0.001) were independent prognostic factors for survival.
Conclusion: The presence of lymphatic metastasis is an unfavourable prognostic factor, while postoperative therapy
with mitotane is a favorable prognostic factor for survival in patients with ACC.
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The more frequent clinical use of ultrasound and comput-
erized tomography have increased the detection of adrenal
tumours. Such adrenal incidentalomas are usually benign
adenomas. Adrenocortical carcinoma (ACC) is rare, but
aggressive malignant endocrine tumour. An ACC is the
second most aggressive endocrine tumour, after anaplastic
thyroid cancer. In addition, an ACC is the second rarest
cancer of the endocrine system, following parathyroid
cancer. The annual incidence of ACC is one per million
population and ACC is responsible for 0.2 % of all cancer-
related mortality [1, 2]. Even though a multimodal ap-
proach is used in the treatment of these patients, in which
surgery has the most important role, the prognosis for
these patients is poor. Most ACC occur as sporadic* Correspondence: loncarz2014@gmail.com
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unless otherwise stated.tumours, but ACC can be part of the rare hereditary
Li-Fraumeni syndrome. The pathogenesis of ACC is not
well-known. In agreement with the characteristics of
benign tumours, ACC can be hormonally-active (func-
tional) or hormonally-inactive (non-functional). Approxi-
mately 70 % of all ACC are hormonally active, and present
in greater than one-half of cases with Cushing's syndrome
[3, 4]. The most common first sign of a hormonally-
inactive ACC is abdominal pain [4]. Because ACC is very
rare tumour there are not many institutions that have had
much experience with these tumours, and therefore clin-
ical characteristics, optimal treatment approaches, prog-
nosis, and prognostic factors are still in need of research.
The aims of our study were as follows: present the
demographic and clinical characteristics of patients with
ACC; determine the overall survival rates; analyse the role
of prognostic factors on survival, and identify favourable
and unfavourable predictors of survival.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This cohort study included 72 consecutive patients who
were diagnosed with ACC based on definitive histopath-
ologic findings and who underwent operative treatment
at the Clinical Centre of Serbia between 1996 to 2014.
The following data were collected from patient records,
a specialized database, and other medical documenta-
tion: basic demographic characteristics of the patients
(gender and age); clinical characteristics (stage of the
disease, size and weight of the tumour, presence of lym-
phatic and distant metastases, tumour localization [i.e., left
vs. right side and local tumour infiltration of surrounding
tissues]; operative treatment (type of operation, surgeon
who performed the surgery [i.e., as a prognostic factor
based on experience], re-operation for local recurrence of
the disease, and operative treatment of distant metastases);
other modes of therapy (radiotherapy and chemotherapy);
hormonal activity of the tumour (functional, or non-
functional); and type of hypersecretion of functional
tumours.
ACC was classified into one of four stages. The first
stage included patients with a tumour sized ≤ 5 cm in
diameter and without local or distant metastases. The
second stage included patients with a tumour ≥ 5 cm in
diameter and without infiltration of surrounding tissues,
or local or distant metastases. The third stage included
patients with a tumour of any size but with infiltration
of surrounding tissue or local lymphatic metastasis. The
fourth stage included patients with tumours of any size,
but with infiltration of surrounding tissues and local
lymphatic metastases or distant metastases only. Con-
tinuous variables (age, tumour weight, and tumour size)
were transformed into dichotomous variables based on
distribution. Other variables (stage of disease, surgical
approach, and type of operation) were transformed into
dichotomous variables. Surgical approaches were catego-
rized as extraperitoneal or transperitoneal.
After analysing the stages of disease individually, we
grouped stages I and II together and stages III and IV
together. For the type of operation, we formed two groups
also. The first group included patients with incomplete
resection of the tumour (i.e., a sub-adrenalectomy).
The second group included patients who had an adre-
nalectomy with or without resection of surrounding
tissues.
Mitotane was the only form of chemotherapy, and
when used, the dosage was 4 g/d. Hormonal activity was
measured for all patients pre-operatively. All surgical
procedures were performed by surgeons in highly spe-
cialized tertiary referral centres. Information on whether
or not the patient was alive, and if not, the date of death,
were retrieved through contact with the patients them-
selves, members of their families, and patient’s general
practitioner. Only patients with a cancer-specific causeof death were included in the probability of survival cal-
culation. Median follow-up was 48 months.
The study was approved by the Ethical Committee of
the Faculty of Medicine of the University of Belgrade
and carried out in compliance with the Helsinki declar-
ation. Participants signed an informed consent prior to
enrolment in the study.
Statistical analysis
Kaplan-Meier survival curves and the log-rank test were
used for determining overall survival and the specific
probability of survival for each of the observed variables,
respectively. We then performed univariate Cox regres-
sion analysis to determine which variables were signifi-
cantly associated with length of survival. The variables
which were significantly associated with length of sur-
vival at a p < 0.05 level of significance, were included in
the multivariate regression analysis model to determine
independent prognostic factors of survival.
Results
As shown in Table 1, ACC occurred in women nearly
50 % more often than men.
The highest number of ACC occurred in patients in
their sixth decade of life; the youngest patient with an
ACC was 17 years of age, while the oldest patient was
72 years of age, and the mean age was 50.4 years. Nearly
one-half of the patients had stage II disease; patients
with stage I disease were extremely rare. Approximately
70 % of patients had a tumour ≤ 10 cm in diameter
weighing ≤ 300 gram. At time of diagnosis, ACC lymph-
atic metastases were present in 12 % of patients, while
distant metastases were present in six patients (lung,
n = 3; liver, n = 2; contralateral adrenal gland, n = 1.
Local tumour invasion was present in ≥ 40 % of patients,
which demonstrates the aggressive nature of the tumours.
One patient presented with an IVC thrombus. Two-thirds
of patients were operated through a subcostal laparotomy
approach and 22 % through a transdorsal approach; other
approaches were rarely used. An endoscopic approach
was not used for this group of patients. There was a simi-
lar rate of tumour occurrence on the right and left sides.
Most patients (88 %) underwent potentially radical sur-
gery, while tumour reduction or biopsy was performed in
one of nine patients. All operations were performed by
one of seven specialist surgeons, and ≥ 70 % of the ope-
rations were performed by a surgeon with 10 years of
experience. Transcutaneous radiotherapy was adminis-
tered to only one patient, while two-thirds of the patients
received chemotherapy with mitotane. Following primary
surgery, over a period of 1–6 years, 6 patients underwent
re-operation for local tumour recurrence. In addition, two
patients underwent surgery for distant metastases to
the lungs during this time period. Most of the tumours



































Subcostal laparotomy 48 66.7
Transdorsal lumbotomy sec.Young 16 22.2
Median laparotomy 1 1.4
Bilateral subcostal laparotomy 3 4.2
Lumbotomy sec. Kifer 3 4.2
Transrectal laparotomy 1 1.4
Tumour localization
Left side 34 47.2
Right side 37 51.4
Bilateral 1 1.4
Table 1 Basic demographics and clinical characteristics of
patients with ACC (Continued)
Type of operation
Biopsy 5 7.1
Tumour reduction 3 4.3
Adrenalectomy 50 71.4
Extended adrenalectomy 12 17.1
Surgeons experience
Specialist up to 10 years 21 29.2
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with functional tumours, 16 had Cushing’s syndrome
(hypersecretion of cortisol) one had hypersecretion of sex
hormones, and two had mixed hypersecretion of cortisol
and sex hormones. Most patients had clear symptoms at
diagnosis, while nearly 40 % of patients were asymptom-
atic with general symptoms such as weight loss, anaemia
or fatigue. Of the 44 symptomatic patients, pain was the
predominant symptom in 25, while 19 had clinical mani-
festations of hypersecretion of cortisol (hypertension,
hirsutism, amenorrhea).
Figure 1 shows the overall probability of survival for
patients with ACC. The 6-month, 1-year, 3-year, 5-year,
10-year probabilities of survival were 69.8 %, 52.5 %,
48.2 %, 41.1 %, and 16.4 %, respectively. The median
survival time was 36 months (95 % CI = 13.4–58.5)
and the mean survival time was 61.5 months (95 %
CI = 42.7–80.1).
The results of univariate Cox regression analysis are
presented in Table 2. The variables significantly associ-
ated with patient survival include gender, age, disease
stage, tumour weight, lymphatic and distant metastases,
local tumour invasion, surgical approach, and therapy
with mitotane.
The results of multivariate Cox regression analysis,
which included all variables that were associated with
patient survival at a p < 0.05 level of significance, are
shown in Table 3. The independent prognostic factors of
patient survival include lymphatic metastases (hazard
ratio [HR] = 7.37, 95 % CI = 2.31–23.48) as an un-

















Fig. 1 Kaplan-Meier survival curve for ACC
Table 2 Results of univariate Cox regression analyses
Variable P HR 95 % CI
Gender (male vs. female) 0.028 2.17 1.09–4.32
Age (years) (50+ vs. <50) 0.015 2.40 1.18–4.86
Stage of disease (III–IV vs. I-II) 0.005 2.94 1.39–6.21
Tumour size (mm) (100+ vs. <100) 0.437 1.36 0.62–2.99
Tumour weight (gram) (300+ vs. <300) 0.047 2.26 1.01–5.05
Lymphatic metastasis (present vs. absent) 0.001 4.86 1.88–12.54
Distant metastases (present vs. absent) 0.001 4.31 1.45–12.83
Local infiltration (present vs. absent) 0.001 3.20 1.57–6.52
Surgical approach (extraperitoneal vs.
transperitoneal)
0.022 0.29 0.10–0.84
Localization (right vs. left) 0.251 1.50 0.75–3.01
Type of surgery (biopsy and tumor
reduction vs. adrenalectomy and
extended adrenalectomy)
0.191 0.52 0.20–1.38
Reoperation (yes vs. no) 0.550 0.75 0.29–1.95
Surgeons experience (10+ vs. <10) 0.704 0.86 0.40–1.85




Symptomatic presentation (yes vs. no) 0.536 0.81 0.41–1.60
HR–Hazard ratio; 95 % CI - Confidence interval
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tic factor.
Discussion
Data on the incidence of ACC are limited, but there has
been no increase in incidence, even though there has
been an increase in the number of diagnosed adrenal
tumours and the number of adrenal operations. This
increase in the early diagnosis and operative treatment
of adrenal tumours could in fact be the reason for theTable 3 The prognostic factors for survival in patients with ACC
(multivariate Cox regression analysis)
Variable p HR 95 % CI
Gender (male vs. female) 0.918 1.05 0.43–2.58
Age (years) (50+ vs. <50) 0.593 1.31 0.49–3.54
Stage of disease (III–IV vs. I-II) 0.879 1.15 0.20–6.71
Tumour weight (g) (300+ vs. <300) 0.665 1.35 0.34–5.36
Lymphatic metastasis (present vs. absent) 0.001 7.37 2.31–23.48
Distant metastases (present vs. absent) 0.491 1.82 0.33–10.09
Local infiltration (present vs. absent) 0.306 1.64 0.64–4.23
Surgical approach (extraperitoneal vs.
transperitoneal)
0.381 0.55 0.15–2.09
Mitotane (used vs. not used) 0.001 0.11 0.05–0.27
HR–Hazard ratio; 95 % CI - Confidence interval
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the past 20 years; the incidence has declined from 1.3 to
1.0 per million inhabitants [2].
The gender prevalence in our study corresponds to
data from the literature. Women are affected by ACC
more often than men, with a ratio of 1.2–1.5:1 [1–4].
Even though most patients are in their fifth or sixth dec-
ade of life at the time of diagnosis, with a mean age of
43–56 years, ACC occurs in all age groups, including
children [1–4]. The population-based age-standardized
incidence rate for patients <20 years of age is 0.2 per
million person-years [5].
ACC is rarely diagnosed as stage I. Indeed, in the
current study study only 3 % of patients were diagnosed
in stage I, compered to 6 % according to the literature
[3, 6, 7]. Most patients (approximately 50 %) are diag-
nosed with stage II ACC, as was the case in the current
study and published data [3, 4, 7]. ACC tumours are
usually large in size. The mean size of ACC tumours ac-
cording to published data is ≥ 10 cm [1, 6]. In the
current study, the size of ACC tumours ranged from 3.5
to 23 cm (mean, 9.8 cm; standard deviation [SD],
4.0 cm), and the weight ranged from 15 to 2450 g (mean,
323 g; SD, 481 g). Lymphatic metastases are present in
20 % of patients with ACC at the time of diagnosis,
while distant metastases occur in nearly 30 % of patients
with ACC [1].
The most common sites for distant metastases are in
lungs and liver [8]. Even though, lymphatic metastases
are often present, locoregional lymph node dissection is
not routinely performed, although Reibetanz et al. sug-
gested that locoregional lymph node dessection im-
proves oncologic outcome [9].
The optimal treatment plan for ACC has not been
well-defined. The best results have been achieved with
surgical treatment, which has the most important role in
the treatment of ACC, while additional treatment op-
tions are still a matter of discussion [10]. Surgical treat-
ment is relatively safe, considering that the peri-
operative mortality is approximately 5 % [3]. A subcostal
laparotomy is the most common approach to ACC; a
laparoscopic approach was not used at our institution,
even though we perform laparoscopic surgery for other
indications. Ferreira et al. also reported that a subcostal
extended incision is the best approach for ACC and that
it can be used even for ACC tumours ≥ 15 cm in size
[11]. Laparoscopic adrenalectomy for ACC is associated
with higher recurrence rates, particularly peritoneal
recurrences. For this reason, open adrenalectomy is a
better choice because of the oncologic benefit that
surpasses the short-term benefits of minimally invasive
surgery [12]. Miller et al. reported the mean size of
laparoscopically-removed tumours to be 7 cm, whereas
the size of tumours removed through open adrenalectomywas 12 cm. In the same study, positive margins of resec-
tion were present in 50 % of laparoscopic operations
and ≤ 20 % in open adrenalectomies. Furthermore, there
was a shorter interval before recurrence after laparo-
scopic surgery compared to open surgery (9 months vs.
19 months). For all of these reasons, Miller et al. con-
cluded that laparoscopic surgery should not be attempted
for ACC [13].
Open adrenalectomy is superior to laparoscopic adre-
nalectomy because of a more complete resection of the
tumour [14]. Brix et al. after analyzing 35 laparoscopic
and 117 open adrenalectomies, concluded that for local-
ized ACC tumours ≤ 10 cm in diameter, laparoscopic
adrenalectomy performed by an experienced surgeon is
not inferior to open adrenalectomy [15].
ACC is considered a radioresistant tumour, thus radio-
therapy is rarely used; except as adjuvant radiotherapy to
the tumour bed in patients with incomplete tumour re-
section or ACC metastases as a palliative measure [16].
Data on the results of the application of adjuvant radio-
therapy to the tumour bed in patients with complete re-
section of the tumour are limited; and the results of the
effect of such adjuvant radiotherapy on reducing high
rates of local recurrence of ACC are controversial [17, 18].
In the current study, the 1-, 3-, 5-, and 10-year sur-
vivals in patients with ACC were 52.5 %, 48.2 %, 41.1 %,
and 16.4 %, respectively; the median survival was 36 months
and the mean survival was 61.5 months. Bilimoria et al.
reported a median survival of 32 months and a 5-year sur-
vival of 38 % in patients with ACC, with no evident change
in survival rates between 1985 and 2000 [1]. Tritos et al. re-
ported a median survival of 17 months in patients with
ACC [19]. Tauchmanova et al. found an overall survival of
41 months in patients with ACC [4]. Schulick et al. showed
a median survival of 38 months and a 5-year survival of
37 % for patients with ACC [20]. According to Keskin et al.
the median survival for patients with ACC was 18 months,
while the 1-year survival was 73 % and the 5-year survival
was 48 % [6]. In the current study, the presence of lymph-
atic metastasis was a negative prognostic factor, while post-
operative therapy with mitotane was a positive prognostic
factor of survival for patients with ACC. Keskin et al. re-
ported that the absence of lymphatic metastasis was a
favourable prognostic factor for patients with ACC [6].
Also, Keskin et al. showed that the absence of distant me-
tastases and an early stage of the disease were favourable
prognostic factors. Additionally, Keskin et al. found gender
to be a favourable prognostic factor, because survival length
was five times longer in men than women (58 months vs.
12 months). Based on a multivariate analysis, Bilimoria et al.
demonstrated a high risk of death with an increase in age,
involved margins, and nodal or distant metastasis [1]. The
presence of lymphatic metastases in patients with ACC is
stage III disease. The higher the stage of disease, the worse
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in patients with ACC of 159 months for stage I and II dis-
ease, 26 months for stage III disease, and 5 months for
stage IV disease [2]. Gomez Rivera et al. reported a mean
survival in patients with ACC of 67 months for stage II dis-
ease, 13 months for stage III disease, and 3 months for
stage IV disease [21]. Furthermore, Gomez Rivera at al.
concluded that prognostic factors that worsen survival are
older age, distant metastases, non-surgical treatment and a
locally invasive tumour that involves large veins. Even in
stage IV disease, better survival is expected if an ACC is
resected in toto (R0), but the question that arises is whether
or not there are really negative resection margins in stage
IV disease [8, 22]. Dong et al. do not recommend surgical
treatment for stage IV ACCbecause the prognosis is not
affected; in contrast, surgical treatment in stage I and II
ACC are most effective, but surgery is also recommended
for stage III ACC [7].
The worst prognosis is expected when the tumour
invades large veins (inferior vena cava and renal veins),
which shorten disease-free interval and survival six-fold
compared to patients in whom invasion of veins is not
present [23]. Peri-operative mortality is 13 % when the
inferior vena cava is infiltrated, but experienced sur-
geons should aim for a radical operation even in these
cases [24]. We did not show that the extent of surgery
influenced the survival outcome, even though this is
considered the most important factor with respect to
survival of patients with ACC. Because most of our
patients had complete resection of the tumour, it was
not possible to statistically prove that surgery influenced
survival outcome. Based on the results of regression ana-
lysis, Tritos et al. showed that the absence of metastases
at the time of diagnosis, patients ≤ 54 years of age, and
complete surgical resection are independent prognostic
factors for improved survival in patients with ACC [19].
Resection for cure is reported in 50–75 % of patients
with ACC [3, 7]. The outcome of ACC patients is influ-
enced by the expertise of the surgeons and number of
patients at the institution where the patients undergo
surgery. For this reason, Hermsen et al. emphasize the
relevance of national cooperation and centralized sur-
gery for ACC [25]. Furthermore, Lombardi et al. classi-
fied institutions into high and low-volume centres [26].
High-volume centres annually perform more than ten
adrenalectomies for ACC, and the outcomes are better
in such centres. The survival benefit is not only the con-
sequence of expert surgical treatment, but also the result
of a multidisciplinary approach to ACC which is prac-
ticed in these specialized centres [27]. We could not sta-
tistically analyse this parameter, because all patients
underwent surgery at the same centre, which is in fact
the centre where most patients with ACC are surgically
treated in our country.The use of mitotane is still under debate, although
mitotane is used in greater than one-half of patients with
ACC [3]. Mitotane is usually used as monotherapy, at a
high-dose, which is favourable [28]. Terzolo et al. re-
ported that the application of mitotane extends the
recurrence-free interval in radically-resected ACC pa-
tients [29]. Icard et al. concluded that mitotane is only
beneficial for ACC patients who undergo complete resec-
tion of the tumour [3]. In contrast, Grubbs et al. reported
that the recurrence-free interval is nearly the same for pa-
tients with ACC who underwent surgery and received
mitotane and patients who did not receive mitotane [30].
The hormonal activity of the tumour also influences the
outcome of patients with ACC. According to Berruti et al.
hypercortisolism is a prognostic factor in completely
resected ACC with respect to overall survival and
recurrence-free survival [31]. Icard et al. reported that
precursor-secreting tumours influenced outcome [3].
ACC has a high recurrence rate. Analysing 101 re-
operations for ACC, Erdogan et al. reported prolonged
survival for R0 resection, even if > 1 year elapsed be-
tween the primary operation and recurrence of the dis-
ease [32].
The reported responses to conventional treatment of
ACC have not been favourable. Additionally, an alterna-
tive approach, such as a wide array of chromosomal,
genetic, molecular, and immunohistochemical markers,
has been tested in ACC to identify reliable diagnostic
and prognostic factors [33–35]. Therefore, certain mo-
lecular markers, such as the IGF system, the Wnt path-
way, and p53, may be considered as potential targets for
treatment and available therapeutic options [33].
There were several limitations to the present study. It
would be useful if this study could be conducted as a
multicentric study with a higher number of patients,
because it would allow better analysis of variables with
low occurrences. Additionally, there were missing data
for some variables. In our study histopathological and im-
munochemical parameters were not included, and which
will be presented in forthcoming publication.Conclusion
In conclusion, the presence of lymphatic metastasis at the
time of diagnosis was a negative prognostic factor for sur-
vival, while postoperative therapy with mitotane was a
favourable prognostic factor for survival in patients
with ACC.
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